Cibus Announces Proposed Public Offering of Class A Common Stock and Pre-Funded Warrants

Celcuity Inc. reported Q4 and FY2025 financial results and provided a corporate update. The FDA accepted Celcuity's NDA for gedatolisib in HR+/HER2-/PIK3CA wild-type advanced breast cancer, granting Priority Review with a PDUFA goal date of July 17, 2026. Topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 study are expected in Q2 2026. Management will host a webcast and conference call today at 4:30 p.m. EDT.